Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739182 | 0.84 | CYP1A2 (0.48) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL13737910 | 0.84 | CYP1A2 (0.48) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL4052149 | 0.84 | CYP1A2 (0.48) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL24633577 | 0.84 | CYP1A2 (0.48) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL23797313 | 0.84 | PTPN1 (0.51) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL10259445 | 0.83 | CYP1A2 (0.68) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL20047604 | 0.81 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL23797292 | 0.81 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL7246121 | 0.81 | PTPN1 (0.49) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL13737717 | 0.81 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139478-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| CN-111201245-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4248965-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3676297-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20200331900-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2020-10-22 | — | — | US | disclosed |
| EP-3676297-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111201245-A | Compounds, compositions and methods | 戴纳立制药公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-2736885-B1 | QUINOLINE-, QUINOXALINE OR BENZOTHIAZOLE BASED CYSTEINYL LEUKOTRIENE ANTAGONISTS (LTC4) | SUN PHARMA ADVANCED RES CO LTD (IN) | 2020-03-25 | — | — | EP | disclosed |
| WO-2019046779-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-103842344-B | Based on quinoline, quinoxaline or the cysteinyl leukotriene antagonist of benzo [c] thiazole | 太阳医药高级研究有限公司 | 2016-08-03 | — | — | CN | disclosed |
| EP-0699188-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1996-03-06 | — | — | EP | disclosed |
| WO-1996002506-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1996-02-01 | — | — | WO | disclosed |
| US-5438141-A | Antiasthmatic agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1995-08-01 | — | — | US | disclosed |
| EP-0643045-A1 | Quinoline derivatives as leukoriene antagonists | CIBA-GEIGY AG (CH) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994027968-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994000446-A1 | FLUORINATED QUINOLINE INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-01-06 | — | — | WO | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| WO-1993021159-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| EP-0565185-A1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1993-10-13 | — | — | EP | disclosed |
| US-5252585-A | Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139478-B2 | Compounds, compositions and methods | EIF4EBP1, EIF4B, EIF4E | CYP1A2 3176/4885KDM4E 2319/4885LMNA 2427/4885 |
| US-20200331900-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | CYP1A2 3176/4885KDM4E 2319/4885LMNA 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.